Mucormycosis clinical trials
The registry lists 32 studies for Mucormycosis across more than 10 countries. 8 are recruiting or about to start. 23 of them are mainly about Mucormycosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-23.
Get an email when these change. Save the Mucormycosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Pfizer (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Post Graduate Institute of Medical Education and Research, Chandigarh (2) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · Merck Sharp & Dohme LLC (1) · University Hospital, Montpellier (1) · Tishreen University (1) · Latakia University (1)
What is being tested here
Drugs under test in Mucormycosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Isavuconazole | 1 | 1 | 2 |
| Posaconazole | 0 | 0 | 2 |
| Deferasirox | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Nov 2026Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction. · Latakia University
Who these studies take
Of the 5 Mucormycosis studies recruiting now, 0 (0%) set no upper age limit and 4 (80%) stop at 75 or younger. 2 (40%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (20%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (40%) | 2 (40%) |
| 18 | 5 (100%) | 5 (100%) |
| 30 | 4 (80%) | 4 (80%) |
| 40 | 4 (80%) | 4 (80%) |
| 50 | 4 (80%) | 4 (80%) |
| 65 | 2 (40%) | 2 (40%) |
| 75 | 1 (20%) | 1 (20%) |
| 85 | 1 (20%) | 1 (20%) |
Across all 32 studies, recruiting or not: 28% stop at 75 or younger and 22% at 65; 41% take children; 0% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 32 of 32. search them.
- Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 ProjectRecruitingNCT068781441 country
- Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.RecruitingNCT07654647Not applicable1 country
- Biomarkers for Invasive MucormycosisRecruitingNCT054060371 country
- Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and SafetyRecruitingNCT071855031 country
- Isavuconazole in Critically Ill Patients: Efficacy and SafetyNot yet recruitingNCT07080359
- Antifungal Drugs in Pulmonary MucormycosisNot yet recruitingNCT06756191Phase 4
- Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in ChildrenRecruitingNCT06440915Not applicable1 country
- Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary MucormycosisEnrolling by invitationNCT06495905Not applicable1 country
- Mucorales PCR Screening in At-risk Hematology PatientsCompletedNCT05925660Not applicable1 country
- Rehabilitation With an Obturator in Maxillary DefectsCompletedNCT065157431 country
- Amphotericin Versus Posaconazole for Pulmonary MucormycosisCompletedNCT05468372Phase 21 country
- Post Marketing Surveillance (PMS) Study of Cresemba in Korea.CompletedNCT047444541 country
- Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From ChinaCompletedNCT069001141 country
- A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.CompletedNCT045509365 countries
- Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety StudyActive, not recruitingNCT071917561 country
- A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric ParticipantsCompletedNCT03816176Phase 23 countries
- World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in EgyptCompletedNCT06267326Phase 1/21 country
- Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary MucormycosisCompletedNCT04502381Phase 21 country
- COVID-19 and Rhino-orbital MucormycosisCompletedNCT052129611 country
- The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) StudyCompletedNCT00419770Phase 21 country
- Post-COVID-19 Mucormycosis in Critical CareCompletedNCT059110351 country
- Mucormycosis in COVID-19CompletedNCT049354631 country
- Mucormycosis in ICUCompletedNCT033876961 country
- Evaluation of Using 3D Printed PEEK Facial Implants in Repairing Maxillofacial DeformitiesCompletedNCT053484341 country
- Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in IranStatus unknownNCT050976641 country
- COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University HospitalCompletedNCT050740431 country
- Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep MycosisCompletedNCT03471988Phase 31 country
- Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICUCompletedNCT043682211 country
- Prospective Evaluation of a New Molecular Tool for Early Diagnosis of MucormycosisCompletedNCT02845934Not applicable1 country
- Emerging Invasive Fungal Infections in Critically Ill PatientsCompletedNCT046475391 country
- Descriptive Epidemiology on Management of MucormycosisCompletedNCT034290231 country
- PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)CompletedNCT00034671Phase 2